Close Menu

NEW YORK (GenomeWeb News) – Illumina's second-quarter revenues retreated 2 percent year over year, but beat the consensus Wall Street estimate, the company reported after the close of the market on Tuesday.

For the three months ended July 1, the San Diego firm had revenues of $280.6 million, compared to $287.5 million a year ago, and above analyst estimates of $278.7 million. Product revenues slid to $258.8 million from $269.9 million a year ago, while service and other revenues rose to $21.8 million from $17.6 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A new blood test might be able to detect the presence of some 50 cancers, according to New Scientist.

Undark looks into how coronavirus-related shutdowns are affecting field researchers.

In PNAS this week: strategies to design DNA oligonucleotide probes for bacteria, Vibrio cholerae evolution in Haiti, and more.

NPR reports that graduate students in the US are helping with SARS-CoV-2 testing.